---
document_datetime: 2023-09-21 19:14:43
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/emtriva-epar-procedural-steps-taken-authorisation_en.pdf
document_name: emtriva-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5028645
conversion_datetime: 2025-12-27 16:25:34.579109
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Triangle Pharma Limited submitted on 6 December 2002 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Emtriva (emtricitabine),  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  20  February 2002,  this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No (EEC) 2309/93 of 22 July 1993 as amended. On 5 February 2003, the applicant informed the EMEA that further to the acquisition of Triangle Pharma Limited by Gilead Sciences Inc, the applicant for this application was changed to Gilead Sciences International Limited.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Dr. I. Hudson

## Scientific Advice:

The applicant did not seek scientific advice at the CPMP.

## Licensing status:

Emtriva was not licensed in any country at the time of submission of the application. The product has been given a Marketing Authorisation in the United States on 2 July 2003.

## 2. Steps taken for the assessment of the product

- The  applicant  submitted  to  the  CPMP  a  request  for  an  accelerated  procedure  dated  26 November  2002  according  to  the  CPMP  guidance  on  'accelerated  evaluation  of  products indicated  for  serious  diseases  (life-threatening  or  heavy  disabling  diseases),  CPMP/495/96' rev.1 dated 18 September 2001. The CPMP, during its 17 - 18 December 2002 meeting, agreed to  consider  the  possibility  to  adopt  rapidly  an  opinion  based  on  the  recommendation  of  the Rapporteur and Co-rapporteur in their respective Assessment Reports.
- The procedure started on 6 January 2003.
- The Rapporteur's first Assessment Report was circulated to all CPMP members on 20 February 2003. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 11 March 2003.
- During the meeting on 23-25 April 2003, the CPMP, on the basis of the recommendation of the Rapporteur and Co-rapporteur in their respective Assessment Reports, agreed that the data did not support a rapid adoption of an opinion. The CPMP agreed therefore on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 25 April 2003.
- The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 14 May 2003.
- The summary report of the inspection carried out at the manufacturing site for the oral solution between 3 and 6 June 2003 was issued on 18 July 2003.
- The  Rapporteur/co-rapporteur  circulated  the  response  Assessment  Report  on  the  applicant's responses to the List of Questions to all CPMP members on 26 June 2003.

Co-Rapporteur:    Prof. B. Silva-Lima

<div style=\"page-break-after: always\"></div>

- The applicant provided a letter of undertaking of the follow-up measures to be fulfilled postauthorisation on 23 July 2003.
- During the meeting on 22 - 24 July 2003 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Emtriva 200 mg hard capsules and 10 mg/ml oral solution on 24 July 2003.
- The  CPMP  opinion  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission, which adopted the corresponding Decision on 24 October 2003.